May 11, 2019CellsOpen Access

Protective Effects of Licochalcone A Ameliorates Obesity and Non-Alcoholic Fatty Liver Disease Via Promotion of the Sirt-1/AMPK Pathway in Mice Fed a High-Fat Diet

View Full Paper

Ask AI

Bookmark

Why the study?

The effects of licochalcone A on reducing weight gain and improving nonalcoholic fatty liver disease remained unclear.

Does licochalcone A ameliorate obesity and NAFLD in mice fed a high-fat diet?

Structured PICO

Does licochalcone A ameliorate obesity and NAFLD in mice fed a high-fat diet?

Population

Male C57BL/6 mice fed a high-fat diet (HFD) to induce obesity and NAFLD, and a fatty liver cell model using HepG2 hepatocytes incubated with oleic acid

Intervention

Licochalcone A (intraperitoneal injection in vivo, cell treatment in vitro)

Comparator

HFD-treated mice without licochalcone A / untreated cells

Outcome

Body weight, adipose tissue weights, hepatocyte steatosis, liver tissue weight, and lipid droplet accumulationsurrogate

Licochalcone A shows potential in ameliorating obesity and NAFLD through the activation of the sirt-1/AMPK pathway in preclinical models.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Should not change practice in obesity or NAFLD; leaves open efficacy of licochalcone A in humans.

Cite This Study

Liou et al. (2019) studied this question.

synapsesocial.com/papers/6a855464f0d179eaafb551d4 https://doi.org/10.3390/cells8050447

View Full Paper

Ask AI

Bookmark

Protective Effects of Licochalcone A Ameliorates Obesity and Non-Alcoholic Fatty Liver Disease Via Promotion of the Sirt-1/AMPK Pathway in Mice Fed a High-Fat Diet

Structured PICO

Discussion

Implication

Cite This Study

Protective Effects of Licochalcone A Ameliorates Obesity and Non-Alcoholic Fatty Liver Disease Via Promotion of the Sirt-1/AMPK Pathway in Mice Fed a High-Fat Diet

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider